

**10/516505**

DT05 Rec'd PCT/PTO 01 DEC 2004

PTS-0055USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : unassigned Confirmation No.: unassigned  
Applicant : Bennett et al.  
Filed : Herewith  
TC/A.U. : unassigned  
Examiner : unassigned  
Customer No. : 36441  
Title : ANTISENSE MODULATION OF EXTRACELLULAR-SIGNAL-REGULATED KINASE-6 EXPRESSION

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of documents AL-AN and AR-CR are enclosed herewith. This Information Disclosure Statement is submitted less than three months from the filing date of this application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

**REMARKS**

Listed below and provided herewith are previously filed, and co-pending, US Patent applications. These applications and the present application are commonly owned:

- (i) U.S. Patent Application No. 10/174,465, filed June 17, 2002; U.S. Patent Publication No. 2003-0232772, published December 18, 2003
- (ii) U.S. Patent Application No. 10/348,431, filed January 17, 2003; U.S. Patent Publication No. 2003-0232778, published December 18, 2003

Listed below are documents cited in the International Search Report dated August 18, 2003 in the counterpart International Patent Application No. PCT/US03/16214, filed June 16, 2003. A copy of the Report is enclosed together with copies of the documents.

- (i) U.S. Patent No. 5,801,154, issued September 1, 1998
- (ii) U.S. Patent No. 6,030,822, issued February 29, 2000
- (iii) U.S. Patent Publication No. 2002-0107218, published August 1, 2002
- (iv) DINEV et al., "Extracellular signal regulated kinase 5 (ERK5) is required for the differentiation of muscle cell", EMBO Reports September 2001 2:829-834

(v) FRITZ et al., "Cationic polystyrene nonparticles: Preparation and characterization of a model drug carrier system for antisense oligonucleotides", J. Colloid and Interface Sci. November 15, 1997 195:272-288

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for Applicants

By Mary E. Bak  
Mary E. Bak  
Registration No. 31,215  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Telephone: (215) 540-9200  
Telefacsimile: (215) 540-5818

10/516505

DT05 Rec'd PCT/PTO 01 DEC 2004

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet 1 of 4

Application Number	unassigned
Filing Date	Herewith
First Named Inventor	Bennett et al.
Art Unit	unassigned
Examiner Name	unassigned

Attorney Docket Number PTS-0055USA

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
AA	US- 5,459,036		10-17-1995	Lechner et al.	
AB	US- 5,801,154		09-01-1998	Baracchini et al.	
AC	US- 6,030,822		02-29-2000	Lechner et al.	
AD	US- 6,140,124		10-31-2000	Monia et al.	
AE	US- 6,172,216		01-09-2001	Bennett et al.	
AF	US- 6,579,856		06-17-2003	Mercola et al.	
AG	US- 2003-0232772-A1		06-17-2002	Bennett et al.	
AH	US- 2003-0232778-A1		12-18-2002	Marcusson et al.	
	US-				

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
AL	EP-1174129		07-17-2000	Zenner et al.		
AM	WO-01/57278		01-01-2001	Penn et al.		
AN	WO-03/106711		12-24-2003	Bennett et al.		

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

<p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(Use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				<i>Application Number</i>	unassigned
				<i>Filing Date</i>	Herewith
				<i>First Named Inventor</i>	Bennett et al.
				<i>Group Art Unit</i>	unassigned
				<i>Examiner Name</i>	unassigned
Sheet	2	of	4	<i>Attorney Docket Number</i>	PTS-0055USA

**NONPATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AR	BOPPART et al., "Marathon running transiently increases c-Jun NH <sub>2</sub> -terminal kinase and p38 activities in human skeletal muscles", <i>J. Physiol.</i> <b>August 1, 2000</b> 526 Pt. 3:663-669	
	AS	CONRAD et al., "Novel regulation of p38 gamma by dopamine D2 receptors during hypoxia", <i>Cell Signal.</i> <b>July 2000</b> 12:463-467	
	AT	DINEV et al., "Extracellular signal regulated kinase 5 (ERK5) is required for the differentiation of muscle cell", <i>EMBO Reports</i> <b>September 2001</b> 2:829-834	
	AU	ENGLISH et al., Pharmacological inhibitors of MAPK pathways", <i>Trends Pharm. Sci.</i> <b>January 2002</b> 23:40-45	
	AV	ENSLEN et al., "Molecular determinants that mediate selective activation of p38 MAP kinase isoforms", <i>EMBO J.</i> <b>March 15, 2000</b> 19:1301-1311	
	AW	FRITZ et al., "Cationic polystyrene nonparticles: Preparation and characterization of a model drug carrier system for antisense oligonucleotides", <i>J. Colloid and Interface Sci.</i> <b>November 15, 1997</b> 195:272-288	
	AX	GOEDERT et al., "Assignment of the human stress-activated protein kinase-3 gene (SAPK3) to chromosome 22q13.3 by fluorescence in situ hybridization", <i>Genomics</i> <b>May 1, 1997</b> 41:501-502	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

10/516505  
DT05 Rec'd PCT/PTO 01 DEC 2004

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	unassigned
				<i>Filing Date</i>	Herewith
				<i>First Named Inventor</i>	Bennett et al.
				<i>Group Art Unit</i>	unassigned
				<i>Examiner Name</i>	unassigned
Sheet	3	of	4	<i>Attorney Docket Number</i>	PTS-0055USA

**NONPATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AY	GOEDERT et al., "Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases", <i>FEBS Lett. June 2, 1997</i> 409:57-62	
	AZ	HADDAD, J.J., "VX-745. Vertex Pharmaceuticals", <i>Curr. Opin. Investig. Drugs August 2001</i> 2:1070-1076	
	BR	LECHNER et al., "ERK6, a mutagen-activated protein kinase involved in C2C12 myoblast differentiation", <i>Proc. Natl. Acad. Sci. USA April 30, 1996</i> 93:4355-4359	
	BS	LECHNER et al., Genbank Accession No. X79483, <i>May 27, 1994</i>	
	BT	LEE et al., "Distinct localization of SAPK isoforms in neurons of adult mouse brain implies multiple signaling modes of SAPK pathway", <i>Brain Res. Mol. Brain Res. June 18, 1999</i> 70:116-124	
	BU	LI et al., "The primary structure of p38 gamma: a new member of p38 group of MAP kinases", <i>Biochem. Biophys. Res. Commun. November 12, 1996</i> 228:334-340	
	BV	MARINISSEN et al., "A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-jun NH2-terminal kinas, p38γ, and extracellular signal-regulated kinase 5", <i>Mol. And Cell. Bio. June 1999</i> 19(6):4289-4301	
	BW	MARINISSEN et al., "Regulation of gene expression by the small GTPase Rho through the ERK6 (p38gamma) MAP kinase pathway", <i>Genes Dev. March 1, 2001</i> 15:535-553	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

**SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

10/516505

DT05 Rec'd PCT/PTO 01 DEC 2004

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	unassigned
				<i>Filing Date</i>	Herewith
				<i>First Named Inventor</i>	Bennett et al.
				<i>Group Art Unit</i>	unassigned
				<i>Examiner Name</i>	unassigned
Sheet	4	of	4	<i>Attorney Docket Number</i>	PTS-0055USA

NONPATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	BX	MILLIGAN et al., "Current concepts in antisense drug design", <i>J. of Med. Chem.</i> <b>July 9, 1993</b> 36:1923-1937			
	BY	PILLAIRE et al., "Cisplatin and UV radiation induce activation of the stress-activated protein kinase, p38s in human melanoma cells", <i>Biochem. And Biophys. Research Comm.</i> <b>November 30, 2000</b> 278:724-728			
	BZ	SAKABE et al., "Potent transforming activity of the small GTP-binding protein Rit in NIH 3T3 cells: evidence for a role of a p38γ-dependent signaling pathway", <i>FEBS Lett.</i> <b>January 30, 2002</b> 511:15-20			
	CR	WANG et al., "Involvement of the MKK6-p38γ cascade in γ-radiation-induced cell cycle arrest", <i>Mol. And Cell. Bio.</i> <b>July 2000</b> 20:4543-4552			

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.  
**SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.